Genmab — Marts 2021
-
-
Who knew investment carries risc? Mogens Lykketoft?
-
The drug, now dubbed Abecma, will sport a list price of $419,500. / the bcma car-t https://endpts.com/bristol-myers-squibb-lands-once-high-stakes-approval-on-bcma-car-t-jj-is-breathing-down-its-neck/
-
Gad vide hvorfor, vi får en BM på en SEC filing af årsregnskabet, når GEN ikke engang fortæller om IND’erne længere...?
-
BM på filing af årsregnskab er de forpligtet til når de har US listing...
-
Makes sense - det er i hvert fald ikke den mest ophidsende meddelelse
-
...any CRs yet?
-
God morgen.
-
Asien: Blandet landhandel på baggrund af pandemi-udviklinghttps://www.proinvestor.com/investornyt/673614/asien-blandet-landhandel-pa-baggrund-af-pandemi-udvikling
-
Tirsdagens aviser med Mærsk, Ørsted og GN https://www.proinvestor.com/investornyt/673613/tirsdagens-aviser-med-maersk-orsted-og-gn
-
Genmab Announces European Marketing Authorization for Kesimpta
(ofatumumab) in Relapsing Multiple Sclerosis -
Genmab-partner får godkendelse til at markedsføre sclerosemiddel - NY
https://www.proinvestor.com/investornyt/673621/genmab-partner-far-godkendelse-til-at-markedsfore-sclerosemiddel-ny
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind